Suppr超能文献

四十年造血干细胞移植:巴塞尔经验回顾。

Forty years of haematopoietic stem cell transplantation: a review of the Basel experience.

机构信息

Behandlungszentrum Stammzelltransplantation, Basel University Hospital, SWITZERLAND;

出版信息

Swiss Med Wkly. 2014 Feb 24;144:w13928. doi: 10.4414/smw.2014.13928.

Abstract

The purpose of this study was to examine changes in haematopoietic stem cell transplant (HSCT) characteristics and outcome in our combined paediatric and adult programme over the past four decades, since its implementation in 1973. The total number of transplant procedures rose from 109 in the first decade (1973-82) to 939 in the last decade (2003-12). Transplant characteristics changed significantly over time: patient age increased, peripheral blood largely replaced bone marrow as stem cell source, unrelated donors became an alternative to matched siblings, and patients are increasingly transplanted in more advanced disease stages. Advances such as improved supportive care and histocompatibility typing resulted in a steady decrease of transplant-related mortality after allogeneic HSCT (43% in the first decade, 22% in the last decade). Despite this, unadjusted survival rates were stable in the last three decades for allogeneic HSCT (approximately 50% 5-year survival) and in the last two decades for autologous HSCT (approximately 60% 5-year survival). After adjustment for covariates such as donor type, age and stage, the relative risk of treatment failure continuously dropped (for allogeneic HSCT: first decade 1.0, second decade 0.58, third decade 0.51, last decade 0.41). Collectively, these data suggest that improvements in peri- and post-transplant care have allowed considerable extension of transplant indications without having a negative impact on outcome.

摘要

本研究旨在探讨过去四十年间,自 1973 年开展造血干细胞移植(HSCT)以来,我们的儿科和成人联合项目中 HSCT 特征和结果的变化。移植例数从第一个十年(1973-82 年)的 109 例增加到最后一个十年(2003-12 年)的 939 例。移植特征随时间发生了显著变化:患者年龄增加,外周血逐渐取代骨髓作为干细胞来源,非亲缘供者成为匹配同胞供者的替代方案,且患者越来越多地在疾病更晚期接受移植。由于支持性治疗和组织相容性配型的进步,异基因 HSCT 后的移植相关死亡率稳步下降(第一个十年为 43%,最后一个十年为 22%)。尽管如此,在过去三个十年中,异基因 HSCT 的未调整生存率保持稳定(约 50%的 5 年生存率),在过去两个十年中,自体 HSCT 的生存率保持稳定(约 60%的 5 年生存率)。在调整了供者类型、年龄和疾病分期等协变量后,治疗失败的相对风险持续下降(对于异基因 HSCT:第一个十年为 1.0,第二个十年为 0.58,第三个十年为 0.51,最后一个十年为 0.41)。总的来说,这些数据表明,移植前后护理的改进使得移植适应证得以显著扩展,而不会对结果产生负面影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验